Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci169315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Kyle Vaccaro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, CD47 Antigen, Macrophages. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Multiple sources.
Abstract (Originalsprache)
Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed an unbiased, high-throughput screening platform to identify drugs that render lung cancer cells more vulnerable to macrophage attack, and we found that therapeutic synergy exists between genotype-directed therapies and anti-CD47 antibodies. In validation studies, we found that the combination of genotype-directed therapies and CD47 blockade elicited robust phagocytosis and eliminated persister cells in vitro and maximized antitumor responses in vivo. Importantly, these findings broadly applied to lung cancers with various RTK/MAPK pathway alterations — including EGFR mutations, ALK fusions, or KRAS G12C mutations. We observed downregulation of β2-microglobulin and CD73 as molecular mechanisms contributing to enhanced sensitivity to macrophage attack. Our findings demonstrate that dual inhibition of the RTK/MAPK pathway and the CD47/SIRPa axis is a promising immunotherapeutic strategy. Our study provides strong rationale for testing this therapeutic combination in patients with lung cancers bearing driver mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Förderung
- NCI NIH HHS
- Multiple sources
Zitieren
APA
Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., Phan, N., Bell, G. W., Hata, A. N., & Weiskopf, K. (2024). Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. https://doi.org/10.1172/jci169315
Vancouver
Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, et al. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. 2024. doi:10.1172/jci169315
BibTeX
@article{Vaccaro2024,
author = {Vaccaro, Kyle and Allen, Juliet and Whitfield, Troy W and Maoz, Asaf and Reeves, Sarah and Velarde, José and Yang, Dian and Meglan, Anna and Ribeiro, Juliano and Blandin, Jasmine and Phan, Nicole and Bell, George W and Hata, Aaron N and Weiskopf, Kipp},
title = {Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci169315}
}
EUVIMED